- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Prostate Cancer in the Family Tree Increases A Woman's Risk of Breast Cancer
A study, published in the journal Cancer, found that women with a family history of both breast and prostate cancer among first-degree relatives have an almost 2-fold increase in risk of developing breast cancer themselves.
CANCER
Having a family history of prostate cancer among first-degree relatives may increase a woman's risk of developing breast cancer. That is the conclusion of a new study published early online in , a peer-reviewed journal of the American Cancer Society. The study's results indicate that clinicians should take a complete family history of all cancers--even those in family members of the opposite sex--to help assess a patient's risk of developing cancer.
Evidence suggests that the risk of developing breast and prostate cancer is increased among individuals with a family history of the same disease, particularly among first-degree relatives. However, less is known about the relationship between breast and prostate cancer within families.
Link to the press release on EurekAlert!:
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
